Sexually Transmitted Infections (STIs)

7

Review clinical trials related to Sexually Transmitted Infections (STIs). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

STI Testing to Enhance PrEP Use in Pregnancy

The investigators are conducting a study in Botswana to see if offering STI testing along with expanded HIV prevention options (PrEP) helps more pregnant women start and continue using PrEP during and after pregnancy. Pregnant women (n=600) seeking antenatal care in Botswana will be enrolled and randomly assigned to receive the standard of care (standard STI assessment with no STI testing) versus STI testing for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis during pregnancy and postpartum. The investigators' hypothesis is that providing STI testing alongside PrEP offer will encourage more women to start and continue using PrEP.

Participants needed: 600
Trial details
Phase: Phase 3Biological sex: FemaleType: InterventionalSponsor: Botswana Harvard AIDS Institute PartnershipUpdated: Jun 11, 2026Locations: 1
Eligibility criteria

Pregnant and seeking antenatal care [+6]

Male gender [+6]

Status: Recruiting

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections

The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.

Participants needed: 760
Trial details
Phase: Phase 4Age: 13-29Biological sex: FemaleType: InterventionalSponsor: WestatUpdated: May 15, 2026Locations: 13
Eligibility criteria

Age 13-29 years, inclusive; [+6]

Is male; [+8]

Status: Recruiting

Integrating Sexual Pleasure Into Harm Reduction Services for Men Who Have Sex With Men and Transgender Persons Who Engage in Chemsex or Substance Use in Thailand

The study evaluates the integration of a sexual pleasure-based approach into harm reduction services for MSM and transgender persons engaging in chemsex or substance use in Thailand, using the "Pleasuremeter" tool to improve sexual health and related outcomes.

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Institute of HIV Research and Innovation Foundation, ThailandUpdated: Apr 8, 2026Locations: 1
Eligibility criteria

MSM, transgender women, transgender men, or non-binary persons [+3]

Status: Recruiting

The Implementation of a Trans-tailored Harm Reduction Service for Transgender Persons in Relation to chemsEX and Substance Use (iT-REX)

This study evaluates a comprehensive transgender-tailored harm reduction service for transgender women, transgender men, and non-binary individuals engaging in chemsex or substance use in Thailand, focusing on PrEP uptake, HIV/STI outcomes, mental health, and socio-legal impacts.

Participants needed: 140
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Institute of HIV Research and Innovation Foundation, ThailandUpdated: Apr 6, 2026Locations: 1
Eligibility criteria

Self-identified transgender women, transgender men, or non-binary persons [+4]

Status: Recruiting

Host Led Harm Reduction Approach Among Men Who Have Sex With Men Who Engaged in Chemsex in Bangkok, Thailand: A Pre-Implementation Study

This study evaluates the pre-implementation phase of a host-led harm reduction model for men who have sex with men (MSM) engaging in chemsex in Bangkok, Thailand, focusing on understanding harms, contexts, and needs to develop a tailored intervention.

Participants needed: 76
Trial details
Age: 18+Biological sex: MaleType: ObservationalSponsor: Institute of HIV Research and Innovation Foundation, ThailandUpdated: Apr 6, 2026Locations: 1
Eligibility criteria

MSM aged ≥18 years [+5]

Status: Recruiting

Pre-implementation Study to Develop Trans-tailored Services for Transgender Persons in Relation to chemsEX

The study is a pre-implementation cross-sectional study exploring chemsex behaviors among transgender persons and gathering perspectives from multiple stakeholders to inform the development of transgender-tailored harm reduction services.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Institute of HIV Research and Innovation Foundation, ThailandUpdated: Apr 6, 2026Locations: 1
Eligibility criteria

Age ≥18 years [+2]

Status: Recruiting

Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain

Objective: To develop and validate a predictive model for acquiring sexually transmitted infections (STIs) in individuals using HIV pre-exposure prophylaxis (PrEP) within the national program providing this strategy. Methods: Ambispective cohort study, multicentric (23 Spanish hospitals). All PrEP users, with follow-up within the program, will be included. Entry into the program will be considered as the baseline visit. From there, patients are followed quarterly, following the national protocols for monitoring PrEP users in Spain. At each visit, diagnosis of different STIs (serum, pharyngeal swab, urethral or urine sample, rectal swab, endocervical/vaginal swab, ulcer) is performed. Primary outcome variable: development of an STI (Yes/No). The following STIs will be considered: syphilis, Neisseria gonorrhoeae (NG) infection, Chlamydia trachomatis (CT) infection, lymphogranuloma venereum (LGV), Mycoplasma genitalium (MG) infection, genital herpes, hepatitis A, hepatitis B, hepatitis C, HIV infection, and MPOX. Secondary outcome variable: number of diagnosed STIs. In order to determine factors associated with acquiring an STI, multivariate analyses will be conducted using logistic regression. The best models will be analyzed in the validation population. To compare the models, we will follow the Bayesian approach suggested by Benavoli et al.

Participants needed: 9,000
Trial details
Age: 16+Biological sex: AllType: ObservationalSponsor: Hospital Universitario de ValmeUpdated: Mar 6, 2025Locations: 26Duration: 5 Years
Eligibility criteria

All individuals with documented initiation of oral PrEP (daily or event-driven r... [+5]